Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer

The results of the current studies to determine the optimal strategy for metastatic gastric cancer remain contrversial worldwide. Hypothesis: Cytoreductive Gastrectomy After Systemic Therapy will improve survival time for metastasis gastric cancer compared to Systemic Therapy alone.

Trial Details

NCT ID
NCT06768463
Phase
NA
Sponsor
University Medical Center Ho Chi Minh City (UMC)
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Cytoreductive Gastrectomy
Locations (sample)
  • Ho Chi Minh City, Ho Chi Minh, Vietnam|10.82302,106.62965

Key Eligibility Criteria

  • GCLM detected on surgical exploration and demonstrated by histology or cytology
  • Localized peritoneal carcinomatosis (P1 or P2 score), according to the classification of the Japanese Research Society for Gastric Cancer
  • Liver metastasis lesions of maximum diameter ≤5 cm
  • Para-aortic lymph node metastasis below the coeliac axis or above the inferior mesenteric artery (lymph node 16a1/b2 of maximum diameter≥1cm)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →